Treatment of diabetes hasn’t changed so much since the development of first human insulin by Genentech. But Boston-based Intarcia (a partner of Servier and one of the 9 billion-dollar Biotech startups worldwide) has just published positive phase III results of its implantable device aiming at changing how type 2 diabetes are treated.
November 2014: I thought I could have misread the realease, but to my surprise it’s true: France’s biggest private Pharma company has made a $1Bn partnership with a company called Intarcia. 1 Billion seemed an astronomical amount at the time, but since understanding more of what the deal entails, the scale of the partnership is more understandable.
Intarcia presented the results of its two first Phase III results at the 51st European Association for the Study of Diabetes in Stockholm, Sweden.
The trial, called FREEDOM (pretty original title for a trial, ay?), is investigating the efficacy of the active agent ITCA-650 for the treatment of type 2 diabetes.